- Home
- SNTI vs SCNX Comparison
SNTI vs SCNX Comparison
Compare SNTI & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- SCNX
- Stock Information
- Founded
- SNTI 2016
- SCNX 2010
- Country
- SNTI United States
- SCNX United States
- Employees
- SNTI N/A
- SCNX N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- SNTI Health Care
- SCNX Health Care
- Exchange
- SNTI Nasdaq
- SCNX Nasdaq
- Market Cap
- SNTI 85.3M
- SCNX 14.4M
- IPO Year
- SNTI N/A
- SCNX 2020
- Fundamental
- Price
- SNTI $2.21
- SCNX $1.59
- Analyst Decision
- SNTI Strong Buy
- SCNX
- Analyst Count
- SNTI 2
- SCNX 0
- Target Price
- SNTI $8.50
- SCNX N/A
- AVG Volume (30 Days)
- SNTI 380.4K
- SCNX 180.9K
- Earning Date
- SNTI 08-12-2025
- SCNX 08-10-2025
- Dividend Yield
- SNTI N/A
- SCNX N/A
- EPS Growth
- SNTI N/A
- SCNX N/A
- EPS
- SNTI N/A
- SCNX N/A
- Revenue
- SNTI N/A
- SCNX $146,901.00
- Revenue This Year
- SNTI N/A
- SCNX N/A
- Revenue Next Year
- SNTI $150.00
- SCNX N/A
- P/E Ratio
- SNTI N/A
- SCNX N/A
- Revenue Growth
- SNTI N/A
- SCNX N/A
- 52 Week Low
- SNTI $1.52
- SCNX $0.69
- 52 Week High
- SNTI $16.94
- SCNX $23.77
- Technical
- Relative Strength Index (RSI)
- SNTI 43.19
- SCNX N/A
- Support Level
- SNTI $2.10
- SCNX N/A
- Resistance Level
- SNTI $2.43
- SCNX N/A
- Average True Range (ATR)
- SNTI 0.18
- SCNX 0.00
- MACD
- SNTI 0.05
- SCNX 0.00
- Stochastic Oscillator
- SNTI 79.25
- SCNX 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.